Loading...
XHKG1763
Market cap451mUSD
Jan 07, Last price  
10.68HKD
1D
0.56%
1Q
0.38%
IPO
-51.67%
Name

China Isotope & Radiation Corp

Chart & Performance

D1W1MN
XHKG:1763 chart
P/E
8.91
P/S
0.50
EPS
1.13
Div Yield, %
4.02%
Shrs. gr., 5y
2.76%
Rev. gr., 5y
15.43%
Revenues
6.63b
+7.95%
2,152,134,0002,363,122,0002,672,045,0003,238,019,0003,988,904,0004,274,183,0005,143,694,0006,146,172,0006,634,992,000
Net income
371m
-5.43%
254,205,000262,108,000271,454,000322,951,000329,030,000213,582,000335,751,000392,275,000370,967,000
CFO
85m
-90.15%
389,536,000457,633,000429,760,000577,710,000601,891,000291,913,000794,312,000862,659,00084,957,000
Dividend
Sep 27, 20240.0724 HKD/sh

Profile

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Independent Clinical Medical and Laboratory Services, and Other Business. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment provides medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization; and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment sells radiation therapy equipment; and provides related maintenance services. The Independent Clinical Medical and Laboratory Services, and Other Business segment provides independent clinical laboratory services with respect to hepatitis, endocrine, bone metabolism, cardiovascular disease, diabetes, and other diseases to hospitals and other medical institutions. The company was founded in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation.
URL
http://www.china-isotope.com/
IPO date
Jul 06, 2018
Employees
3,264
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,634,992
7.95%
6,146,172
19.49%
Cost of revenue
5,863,086
5,293,418
Unusual Expense (Income)
NOPBT
771,906
852,754
NOPBT Margin
11.63%
13.87%
Operating Taxes
146,307
165,947
Tax Rate
18.95%
19.46%
NOPAT
625,599
686,807
Net income
370,967
-5.43%
392,275
16.84%
Dividends
(140,969)
(120,881)
Dividend yield
3.30%
2.82%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
217,189
46,716
Long-term debt
1,530,534
866,664
Deferred revenue
60,001
Other long-term liabilities
320,128
(79,056)
Net debt
(1,972,314)
(2,875,674)
Cash flow
Cash from operating activities
84,957
862,659
CAPEX
(897,617)
(534,000)
Cash from investing activities
(429,881)
(506,623)
Cash from financing activities
484,365
(291,498)
FCF
(900,242)
323,720
Balance
Cash
2,940,530
2,948,597
Long term investments
779,507
840,457
Excess cash
3,388,287
3,481,745
Stockholders' equity
7,139,328
6,561,273
Invested Capital
5,766,691
4,148,929
ROIC
12.62%
17.58%
ROCE
8.43%
11.15%
EV
Common stock shares outstanding
319,875
319,875
Price
13.36
-0.15%
13.38
-39.18%
Market cap
4,273,529
-0.15%
4,279,926
-39.18%
EV
4,747,223
3,492,248
EBITDA
1,036,257
1,065,782
EV/EBITDA
4.58
3.28
Interest
36,142
34,399
Interest/NOPBT
4.68%
4.03%